drugset / Trial / NCT01911429

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429

Phase 3 Completed 327 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Efficacy and Safety study of Lurasidone in pediatric patients.

Timeline

Start
2013-08
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg
Subject Lurasidone Small molecule 80 mg

Indications